Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study

医学 鼻咽癌 诱导化疗 放化疗 放射治疗 毒性 肿瘤科 化疗 核医学 内科学
作者
Chong Zhao,Jingjing Miao,Yi-Jun Hua,Lin Wang,Fei Han,Li-Xia Lu,Weiwei Xiao,Hai-Jun Wu,Man-Yi Zhu,Shao-Min Huang,Cheng‐Guang Lin,Xiaowu Deng,Conghua Xie
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:104 (4): 836-844 被引量:66
标识
DOI:10.1016/j.ijrobp.2019.03.043
摘要

To evaluate the long-term locoregional control, failure patterns, and late toxicity after reducing the target volume and radiation dose in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT).Previously untreated patients with locoregionally advanced nasopharyngeal carcinoma were recruited into this prospective study. All patients received 2 cycles of IC followed by CCRT. The gross tumor volumes of the nasopharynx (GTVnx) and the neck lymph nodes (GTVnd) were delineated according to the post-IC tumor extension and received full therapeutic doses (68 Gy and 62-66 Gy, respectively). The primary tumor shrinkage after IC was included in the high-risk clinical target volume (CTV1) with a reduced dose of 60 Gy. The locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were calculated using the Kaplan-Meier method. The location and extent of locoregional recurrences were transferred to pretreatment planning computed tomography for dosimetry analysis.There were 112 patients enrolled in this study. The average mean dose of post-GTVnx, post-GTVnd (left), post-GTVnd (right), post-CTV1, and post-low-risk clinical target volume (CTV2) was 75.24, 68.97, 69.16, 70.49, and 63.37 Gy, respectively. With a median follow-up of 125.95 months, the 10-year LRRFS, DMFS and OS were 89.0%, 83.3%, and 75.9%, respectively. There were 8 local recurrences and 6 regional recurrences in 12 patients. All 8 of the local recurrences were in-field; among the 6 regional recurrences, 4 were in-field, 1 was marginal, and 1 was out-field. The most common late toxicities were grade 1 to 2 subcutaneous fibrosis, hearing loss, and xerostomia. No grade 4 late toxicities were observed.Reduction of the target volumes according to the post-IC tumor extension and radiation dose to the post-IC tumor shrinkage could yield excellent long-term locoregional control with limited marginal and out-field recurrences and mild late toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai应助月儿采纳,获得10
1秒前
烟花应助许小六采纳,获得10
1秒前
2秒前
典雅的人生完成签到,获得积分0
2秒前
赘婿应助LanmingQin采纳,获得30
3秒前
星辰大海应助糟糕的妙海采纳,获得10
3秒前
jj发布了新的文献求助10
4秒前
Xdongdong发布了新的文献求助10
4秒前
haichong发布了新的文献求助10
4秒前
4秒前
陈远远完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
jja881发布了新的文献求助10
6秒前
6秒前
杨海菡发布了新的文献求助10
8秒前
9秒前
小二郎应助little_wang采纳,获得10
9秒前
9秒前
ZZZ发布了新的文献求助10
10秒前
10秒前
paul发布了新的文献求助10
10秒前
斯文钢笔应助xxx采纳,获得10
11秒前
搜集达人应助杨海菡采纳,获得10
13秒前
psh发布了新的文献求助10
13秒前
13秒前
13秒前
月儿完成签到,获得积分10
14秒前
14秒前
Deml发布了新的文献求助10
14秒前
15秒前
小杰发布了新的文献求助10
16秒前
16秒前
xmy完成签到,获得积分10
16秒前
17秒前
极光完成签到 ,获得积分10
17秒前
17秒前
科研通AI6.4应助阿若采纳,获得10
18秒前
18秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7288397
求助须知:如何正确求助?哪些是违规求助? 8908118
关于积分的说明 18853649
捐赠科研通 6957135
什么是DOI,文献DOI怎么找? 3208896
关于科研通互助平台的介绍 2378670
邀请新用户注册赠送积分活动 2184667